baber/WOPTO huggingface dataset:
Patent NZ-565641-A (NZ)
Title: Database fragment cloning and management
Inventor: GERBER ROBERT H
IPC: G06F11/14
Filed: 2006-07-20
Abstract: A device-readable storage media contains a computer program comprising device-executable instructions that, when executed by a processor, cause the processor to identify a primary cloned fragment associated with a database object; identify a secondary cloned fragment corresponding to the primary cloned fragment with the secondary cloned fragment being stale relative to the primary cloned fragment and refresh the stale secondary cloned fragment with data in the primary cloned fragment by performing a database operation. The primary cloned fragment has a first plurality of records and a first plurality of update identifiers and each of the first plurality of update identifiers is a member of one of the first plurality of records. The secondary cloned fragment has a second plurality of records and a second plurality of update identifiers. Each of the second plurality of update identifiers is a member of one of the second plurality of records. The refreshing of the stale secondary cloned fragment with data in the primary cloned fragment further comprises identifying a first update identifier of a first record in the first plurality of records included in the primary cloned fragment; identifying a second update identifier of a second record in the second plurality of records in the stale secondary cloned fragment, the second record corresponding to the first record; and determining whether the first record and second record with identical cloned record identifiers are consistent based, at least in part, on whether the first update identifier and the second update identifier are equal. The database operation for refreshing the stale secondary cloned fragment includes batches of operations that incrementally refresh the stale secondary cloned fragment by identifying a collection of records that are inconsistent; determining a complete set of database operations that will modify each record in the collection of records; determining a batch size that specifies a number of records in the stale secondary cloned fragment that are updated with each batch; and incrementally refreshing the stale secondary cloned fragment by committing a plurality of transactions with each transaction affects the number of records specified by the batch size. A device-readable storage media contains a computer program comprising device-executable instructions that, when executed by a processor, cause the processor to divide a database table by automatically generating at least two fragments of a database table; generate a first cloned fragment and a second clone fragment for each of the at least two fragments; distribute the first cloned fragment to a first computing device and the second cloned fragment to a second computing device that is different than the first computing device by executing a structured query language statement; and designate at least one of the cloned fragments for each of the at least two fragments as a primary cloned fragment configured to be used for operations associated with the database table.
Patent NZ-573459-A (NZ)
Title: Eeg analysis system
Inventor: LILEY DAVID TIBOR JULIAN
IPC: A61B5/374
Filed: 2007-06-06
Abstract: A system for displaying activity of a brain is disclosed. The system includes a plurality of electrodes for picking up EEG signals from the brain of a subject; digitising means for converting the EEG signals to a digitised EEG data signal; and computing means. The computing means is configured to (i) segment the EEG signal into either contiguous or overlapping segments comprised of a sequential number of samples of the EEG signal; (ii) represent the EEG segments as a fixed order autoregressive moving average (ARMA) signal representation with an autoregressive order between 8 and 13 and a moving average order between 5 and 11; (iii) generate AR coefficient data and MA coefficient data for the segments of the EEG signal for the fixed order ARMA signal representation; (iv) generate signal representations for the segments of EEG signal by substituting generated AR coefficient data and MA coefficient data for the segments of EEG signal into the fixed order ARMA representation and provide as a driving input to the EEG signal representation with a zero mean unit variance Gaussian random process; (v) generate an ARMA gain value as the root mean square of the amplitude values for the signal representations for the segments of EEG; (vi) generate brain product data representative of input to cortex by dividing the root mean square of the amplitude of the EEG signal for the segments by the ARMA gain value for the signal representations of the EEG segments and (vii) display the brain product data on display means.
Patent NZ-577900-A (NZ)
Title: Remote device identification using resonant frequency
Inventor: BAARMAN DAVID W
IPC: H02J7/02
Filed: 2007-12-28
Abstract: A method for controlling an inductive power supply to supply power to a remote device includes inductively interrogating the remote device with at least one identification frequency which may be one of a plurality of identification frequencies and determining whether the remote device has a resonant frequency at the interrogating frequency. If the remote device does have such a resonant frequency the inductive power supply is operated to supply operating power inductively (wirelessly) to the identified remote device according to an operating parameter based on the outcome of the determination, the operating parameter corresponding to the identified remote device.
Patent NZ-581775-A (NZ)
Title: Submerged water pump oxygenator
Inventor: GLOMSET KARSTEN
IPC: A01K63/04
Filed: 2009-12-09
Abstract: To supply gas into water in sea cages, tanks or ponds a completely submerged water pump 1 pumps water through a venturi oxygen dissolver 2 to which pressurized oxygen or oxygen enriched air is supplied. The oxygenated water is then dispersed 3 into the water surrounding the pump.
Patent NZ-585348-A (NZ)
Title: Heterocycle-substituted piperazino-dihydrothienopyrimidines
Inventor: POUZET PASCALE
IPC: A61P1/00
Filed: 2008-10-16
Abstract: Disclosed is a compound of formula (A) where the substituents are as disclosed in the description. Examples of compounds are [2-(4-benzoxazol-2-yl-piperazin-1-yl)-5-oxo-6,7 -dihydro-5H-5 lambda 4-thieno[3,2-d]pyrimidin-4-yl]-(tetrahydropyran-4-yl)-amine; (R)-2-{ 2-[4-(6-CHLORPYRIDAZIN-3-YL)-PIPERAZIN-1-YL]-5-OXO-6,7-DIHYDRO-5H-5 lambda 4-THIENO[3,2-D]PYRIMIDIN-4-YLAMINO} -3-METHYLBUTAN-1-OL and (R)-2-[2-(4-BENZOXAZOL-2-YL-PIPERAZIN-1-YL)-5-OXO-6,7-DIHYDRO-5H-5 lambda 4-THIENO[3,2-D]PYRIMIDIN-4-YLAMINO]-3-METHYLBUTAN-1-OL. Also disclosed is the use of a compound of formal (A) for the manufacture of a medicament for the treatment of a respiratory or a gastrointestinal disease or complaint; or an inflammatory disease of the joint, skin or eye; or cancer; or a disease of the peripheral or central nervous system, a respiratory or a pulmonary disease which is accompanied by increased mucus production; or an inflammatory and/or obstructive disease of the respiratory tract, COPD, chronic sinusitis, asthma, Crohn's disease and ulcerative colitis, depression, bipolar or manic depression, acute or chronic anxiety state, schizophrenia, Alzheimer's disease, Parkinson's disease, acute or chronic multiple sclerosis; acute or chronic pain; and brain damage caused by stroke, hypoxia, or cranio-cerebral trauma. Further disclosed is a pharmaceutical composition comprising a compound of formula (A).
Patent NZ-585621-A (NZ)
Title: Uses of compositions comprising a dopamine agonist selected from pramipexole, bromocriptine, cabergoline, pergolide, ropinirole and quinagolide, and an atypical antipsychotic drug selected from clozapine, olanzapine, quetiapine and risperidone
Inventor: MCINTOSH DIANE
IPC: A61K31/4045
Filed: 2008-11-05
Abstract: 585621 Disclosed is the use of a dopamine agonist in the manufacture of a medicament for preventing or reducing weight gain associated with administration of an atypical antipsychotic drug, wherein the medicament when administered, is administered simultaneously or sequentially with the atypical antipsychotic drug, wherein the dopamine agonist is selected from the group consisting of pramipexole, bromocriptine, cabergoline, pergolide, ropinirole and quinagolide, and wherein the atypical antipsychotic drug is selected form the group consisting of clozapine, olanzapine, quetiapine and risperidone.
Patent NZ-596858-A (NZ)
Title: Method of and system for managing a group of dairy animals
Inventor: VAN DEN BERG KAREL
IPC: A01K1/00
Filed: 2010-06-14
Abstract: A method and a system (1) for managing a group of dairy animals (10) are disclosed. The system (1) comprises a milking parlour (22). The milking parlour has at least one teat cup for extracting milk from a teat of a dairy animal (10); a milk sensor for measuring a value of at least one milk parameter which is related to the composition of the milk as far as the composition is defined by the amount of protein and/or energy intake by the dairy animal and a control unit, configured to compare the measured value with a criterion; at least one passage for a dairy animal with a remotely operable closure (36; 38). The passage for a dairy animal provides access from the milking parlour to a pasture (4), and the control unit is configured to control the at least one remotely operable closure (36; 38) on the basis of the comparing of the measured value with the criterion.
Patent NZ-599295-A (NZ)
Title: Nebulizer
Inventor: BACH ALEXANDER
IPC: A61M5/24
Filed: 2010-11-22
Abstract: A nebuliser with a counter device (44) which aims to prevent the nebuliser from being opened before the container (3) therein has been sufficiently used or has been emptied thus, potential soiling of the nebulizer can be minimized and/or defined handling can be secured. The nebuliser comprises an insertable container (3) containing the fluid and the nebuliser can be opened for replacing the container (3). A counter device (44) counts operations of the nebuliser and is configured to, in use, block opening of the nebuliser until a predetermined number of operations has been reached or exceeded, and to permit the nebuliser to be opened when the predetermined number of operations has been reached or exceeded.
Patent NZ-603269-A (NZ)
Title: Factor viii polymer conjugates
Inventor: TURECEK PETER
IPC: A61K47/48
Filed: 2009-07-29
Abstract: Disclosed is a composition comprising a conjugate comprising a native Factor VIII modified with a water soluble polymer bound thereto, said water soluble polymer attached to the modified Factor VIII via an oxidised carbohydrate moiety, said modified Factor VIII retaining at least 50% of native FVIII activity, and said composition is substantially free from albumin. Also disclosed is a method of conjugating a water soluble polymer to an oxidised carbohydrate moiety of Factor VIII comprising contacting the oxidised carbohydrate moiety with an activated water soluble polymer under conditions that allow conjugation, wherein said FVIII that has been conjugated to the water soluble polymer retains at least 50% of native FVIII activity.
Patent NZ-610614-A (NZ)
Title: Substituted sodium-1h-pyrazole-5-olate
Inventor: GRIES JÖRG
IPC: C07D403/14
Filed: 2011-11-15
Abstract: Provided is sodium 1-[6-{ morpholin-4-yl)pyrimidin-4-yl]-4-(1H-1,2,3-triazol-1-yl)-1H-pyrazol-5-olate depicted in formula (II). Further provided are processes for preparing the compound and uses of the compound in medicaments or medicaments comprising the compound for treating and/or preventing diseases such as cardiovascular, haematological and renal diseases.
Patent NZ-611174-A (NZ)
Title: Conveying chain for a conveying device
Inventor: STUDER BEAT
IPC: B65G17/38
Filed: 2011-12-19
Abstract: A chain link of a conveying chain that allows pivotability of the chain links so the design of the longitudinal guide device and the associated conveying path may be more flexible and the links to have less ware. The links have a basic body (1) having a first end region (4) which comprises a first coupling section (7) for connecting in an articulated manner to a coupling section of a first adjacent chain link. A second end region (5) comprises a second coupling section (8) for connecting in an articulated manner to a coupling section of a second adjacent chain link. The invention is characterized in that the basic body (1) has an intermediate region (6) which is located between the two end regions (4, 5) and comprises a body section which has flexible elastic properties and is configured such that the first end region (4) is elastically bendable out of the longitudinal direction (L) of the basic body (1) in relation to the second end region (5) or twistable along the longitudinal direction (L) of the basic body (1).
Patent NZ-615912-A (NZ)
Title: Means and methods for diagnosing and treating multiple sclerosis
Inventor: HEMMER BERNHARD
IPC: C07K16/18
Filed: 2012-05-23
Abstract: Discloses a peptide comprising or consisting of at least 8 consecutive amino acid residues of the sequence set forth in SEQ ID NO: 3, the upper limit for the length of said peptide being 100 amino acid residues, provided that said peptide does not consist of the sequence set forth in SEQ ID NO: 3; or a corresponding peptidomimetic, wherein said peptide or peptidomimetic is capable of binding to an anti-KIR4.1 antibody comprised in a sample from a patient having multiple sclerosis or a predisposition thereto wherein: (i) said at least 8 consecutive amino acid residues are a subsequence of an extracellular domain of KIR4.1, said extracellular domain consisting of the sequence set forth in SEQ ID NO: 1 or 2; or (ii) said peptide comprises or consists of the sequence of SEQ ID NO: 1 or 2; wherein the sequences are as defined in the complete specification. Further discloses methods involving the use of said peptide or peptidomimetic for diagnosing multiple sclerosis, screening drugs for multiple sclerosis, or to treat multiple sclerosis.
Patent NZ-629722-A (NZ)
Title: Inhalable dry powders
Inventor: DEHAAN WESLEY H
IPC: A61P11/00
Filed: 2013-02-28
Abstract: Disclosed is a sealed receptacle such as in the form of blisters/capsules for a dry powder inhaler (DPI) with contents consisting of a processable dry powder, wherein said processable dry powder consists of respirable dry particles consisting of a sodium salt selected from the group consisting of sodium citrate, sodium chloride, sodium sulfate, and combinations thereof, an optional excipient, and one or more therapeutic agents (such as fluticasone propionate, salmeterol xinafoate, tiotropium bromide, levofloxacin etc.), wherein at least one of the therapeutic agents is hydrophobic, and wherein the processable dry powder has a volume median geometric diameter (VMGD) of 5 microns or less, and a bulk density of greater than 0.1 g/cm3 to about 1.0 g/cm3; said contents disposed into a plurality of said sealed receptacles at a target fill weight and at a rate of about every 4 seconds or less to produce filled sealed receptacles, wherein the relative standard deviation of the dry powder mass disposed into the receptacles is 3 percent or less; and wherein at least 80% of said sealed receptacles contain said respirable dry powder within 85% to 115% of the target fill weight; and wherein the volume of said receptacle is 400 microliters or less.
Patent NZ-703756-A (NZ)
Title: Uk-2 biosynthetic genes and method for improving uk-2 productivity using the same
Inventor: KOBAYASHI KOEI
IPC: C12Q1/68
Filed: 2013-07-08
Abstract: To provide a production method capable of mass production of UK-2 at low cost, the genomic DNA of Streptoverticillium sp. 3-7, which produces UK-2, was analyzed to identify a region expected to be a UK-2 biosynthetic gene cluster. Moreover, by colony hybridization, DNAs in the region were successfully isolated. Further, the DNAs were used to prepare a strain in which the genes present in the region were disrupted. The strain was found not to produce UK-2. It was verified that the genomic region was the UK-2 biosynthetic gene cluster. Furthermore, Streptoverticillium sp. 3-7 was transformed by introduction of a vector in which the isolated UK-2 biosynthetic gene cluster was inserted. It was also found out that the UK-2 productivity by the transformant was improved about 10 to 60 times or more in comparison with that of the parental strain. Moreover, it was revealed that 2 copies of the UK-2 biosynthetic gene cluster were present per cell in these transformants, respectively.
Patent NZ-703856-A (NZ)
Title: Combinations of antifungal compounds and tea tree oil
Inventor: REUVENI MOSHE
IPC: A01P3/00
Filed: 2011-05-05
Abstract: The disclosure relates to a method for treating a plant infection caused by a fungus of the class ascomycetes, comprising applying to the plant a combination of tea tree oil (TTO) and a synthetic fungicidal compound selected from the group consisting of triazole-based demethylation inhibitors (DMIs) and strobilurin-based Quinone outside Inhibitors (QoIs), wherein the infection is selected from the group consisting of banana plant Black Sigatoka, carrot alternaria, tomato powdery mildew, and pepper powdery mildew.
Patent NZ-713753-A (NZ)
Title: Meat processing device incorporating an x-ray analyzer
Inventor: ELSOEE MAJA KIRSTINE
IPC: G01N33/12
Filed: 2013-07-11
Abstract: A meat processing device comprises a meat processing unit (2) and an external X-ray meat analyzer (6) provided with a housing (8) formed with an inlet (16) connectable with an outlet (4) of the processing unit (2). The housing (8) provides complete shielding of personnel from X-rays except towards the inlet (16) and is movable relative to the processing unit (2) to a first position for analysis at which the unit outlet (4) is collocated with the inlet (16) and at which the processing unit (2) completes the shielding of personnel from X-rays towards the inlet (16).
Patent NZ-721184-A (NZ)
Title: Therapeutic peptides
Inventor: WUCHERPFENNIG KAI W
IPC: A61K39/395
Filed: 2012-09-28
Abstract: Discloses compositions with anti-tumour activity comprising antibodies binding MHC class I polypeptide related sequence A (MICA) defined by either a VH comprising CDRs with the sequence of SEQ ID NO: 172-174-176 and VL comprising CDRs defined by SEQ ID NO: 179-181-183. May further comprise a histone deactylase inhibitor (HDAC). Further discloses use in the manufacture of a medicament for treating cancer.
Patent NZ-731588-A (NZ)
Title: Parasiticidal oral veterinary compositions comprising systemically-acting active agents, methods and uses thereof
Inventor: SOLL MARK
IPC: A01N43/80
Filed: 2013-01-31
Abstract: The claims are directed to a solid soft chewable veterinary composition for treating and/or preventing fleas or ticks infection or infestation in an animal such as a dog comprising: a) fluralaner or a pharmaceutically acceptable salt thereof at a concentration of about 1% to about 20% by weight; and b) a pharmaceutically acceptable carrier, wherein the carrier comprises a binder, a surfactant, a filler and a humectant, wherein the binder is PEG 3350; the surfactant is sodium lauryl sulfate at a concentration of about 1 to about 5% (w/w); the filler is corn starch or pre-gelatinized corn starch or a combination thereof; and the humectant is glycerol. The soft chewable compositions may be formed from a dough-like mixture by suitable forming techniques known in the art, and/or using any other suitable molding techniques.
Patent NZ-735044-A (NZ)
Title: Condensed ring derivative, and preparation method, intermediate, pharmaceutical composition and use thereof
Inventor: XU ZUSHENG
IPC: A61K31/517
Filed: 2016-02-01
Abstract: Disclosed are a condensed ring derivative, and a preparation method, an intermediate, a pharmaceutical composition and a use thereof. The condensed ring derivative of the present invention has a significant inhibitive effect on URAT1, which can effectively alleviate or treat hyperuricemia and other related diseases.
Patent NZ-741741-A (NZ)
Title: High intensity sweeteners
Inventor: PATRON ANDREW
IPC: C12P33/20
Filed: 2016-10-27
Abstract: Disclosed herein are compounds having structural Formula (I), or salts thereof. These compounds are useful as sweet tasting agents and/or sweetness enhancers. Also disclosed are compositions comprising the present compounds and methods of increasing the sweet taste of ingestible compositions. Furthermore, methods for preparing the compounds are also disclosed.
Patent NZ-747599-A (NZ)
Title: Entangling projectiles and systems for their use
Inventor: NORRIS ELWOOD
IPC: F42B7/04
Filed: 2017-03-24
Abstract: A projectile deployment system includes an entangling projectile including a pair of pellets and a tether connecting the pellets. A projectile casing includes a pair of sockets, each socket sized to carry one of the pair of pellets and a selectively activatable pressure source, carried by the projectile casing. The pressure source is capable of expelling the entangling projectile from the projectile casing toward a subject. A launcher carries an activator operable to activate the pressure source to expel the entangling projectile from the projectile casing toward the subject. The projectile casing is removably engageable with the launcher to allow removal of the projectile casing from the launcher after expulsion of the entangling projectile from the projectile casing. The problem this device overcomes is to prevent or at least reduce failed wrap of the pellets and tether. This is achieved by offsetting the two projectiles to different but parallel planes to reduce this risk of collision.
Patent NZ-761330-A (NZ)
Title: Reinforcement system for the concrete lining of the inner shell of a tunnel construction
Inventor: HEYMANN MARTIN
IPC: E21D11/08
Filed: 2018-08-24
Abstract: A self-supporting tunnel reinforcement system comprising tensioning arches (4) formed from at least two arch segments with an adaptable arch length and made from individual steel reinforcing bars. The system also comprises tensioning support bodies (2) connected to the tensioning arches, having support arms for establishing a spacing of the arches with respect to an outer shell (15) or rock wall. The arches support at least an outer reinforcement layer (19), and further optional reinforcement layers (20) separated by spacers (21). The tensioning arches (4) are configured to be expanded and tensioned against the tensioning support bodies (2) to apply a force against the outer shell or rock face wall of the tunnel through fixing blocks (1). The invention provides a self-supporting reinforcement system for the inner concrete lining of a tunnel construction that is simpler to construct, quicker to install, and less expensive than existing systems.